INTRODUCTION
Acute liver failure (ALF) in patients requiring ICU admission is associated with high mortality. The cause of death in the majority of patients is related to multi-organ failure (MOF) and sepsis. [1] [2] [3] Emergency Liver transplantation (ELT) has emerged over the years as the gold standard treatment for patients who are unlikely to survive with standard medical treatment
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This article is protected by copyright. All rights reserved. alone. 4, 5 The determination of prognosis and listing for transplantation is assessed on the basis of prognostic tools of which the King's College Hospital (KCH) and the modified KCH criteria (since 2005) are currently the most widely used worldwide. 6, 7 In light of the mounting evidence supporting the trend of a continuously improving spontaneous survival rates (without ELT) decade after decade, 8 consequent upon an improved understanding of the disease itself, the potential reversibility of liver injury in the absence of a preexisting disease, in particular for acetaminophen overdose ALF, 9 with the enhanced standards of medical management, 10 the actual role and the timing of ELT in ALF, once again, has been in the spotlight, raising questions about the additional benefit of ELT in some categories of patients and about the ability of the KCH criteria in selecting patients to candidate to Liver Transplantation (LT). This is particularly relevant given the shortage of organs available for transplantation, the emergency nature of the surgery, which could compromise the short-term outcome, and the long-term complications associated with a LT.
The short-term survival from an ELT is decidedly poorer compared with an elective transplant procedure for chronic liver disease. [11] [12] [13] The long-term outcomes, defined as survival at 3-and 5-year in most studies, have similarly been reported to be better in those who recovered spontaneously, an observation, which is intuitively predictable as potential spontaneous survivors (SS) would not be exposed to the late complications of a major surgery and immunosuppressive therapy. 14 However, a recent large multi-centre study by Fontana et al 15 has reported an exactly opposite finding, the one of poorer long-term outcomes for the SS, even within the acetaminophen overdose (APAP) ALF group. They concluded that, wherever possible and indicated by the current transplantation criteria, the treatment in ALF patients should preferably be surgical. The long-term follow up data for many of the patients in this
This article is protected by copyright. All rights reserved. study were missing. Therefore, the aims of this study were to determine the long term (post ELT or spontaneous recovery) outcomes in a cohort of ALF patients admitted to a single large tertiary liver center equipped with transplantation facility and an established process of following up these patients over time, in order to confirm or refute this observation.
PATIENTS AND METHODS
Data for this study were retrospectively obtained through archived patient notes in the hospital and the follow up data retrieved through a combination of follow up clinic notes, patient's general physicians and direct telephone contact with patients themselves. This database is updated at regular intervals and has been analysed for other purposes previously. Ethical approval was obtained through Royal Free Hospital NHS Trust ethics review board.
Acute Liver Failure and Transplantation definition ALF was defined by the presence of coagulopathy (INR> 1.5) and hepatic encephalopathy (HE) in patients with no previous liver disease, stratified into the sub-categories of hyperacute, acute and sub-acute liver failure on the basis of the length of the time interval between development of jaundice and progression to encephalopathy (J-E period) of 1, 4, and 12 weeks respectively. For APAP related ALF, where jaundice is rare, this would refer to the interval between the first presentation of symptoms to development of HE.
All the patients were treated with intravenous infusion of N-Acetylcysteine during the first 72 hours after ALF diagnosis. Longer periods of treatment were used for patients with ischemic hepatitis and APAP related ALF, according to response. Fresh Frozen Plasma was administered only to patients who fulfilled the KCH criteria when an invasive procedure was necessary. KCH criteria, or UK modified KCH Criteria since 2005, were used to assess poor prog-
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This article is protected by copyright. All rights reserved. nosis and for listing for ELT. 6, 7 All the patients were regularly assessed in order to determine the best strategy for ALF management, whether conservative (organ support) or surgical (ELT). Patients were considered for ELT only when they fulfilled the KCH criteria, which was dynamically applied. For difficult cases where ambiguity existed around issues related to listing for ELT, a multidisciplinary approach was adopted to identify those who would be unlikely to benefit from ELT, taking into account the clinical characteristics, severity of illness and psychosocial factors that would preclude ELT despite patients meeting the KCH criteria.
When patients fulfilled eligibility and transplantation criteria, they were listed on the UK National Register for Liver Transplantation. On the contrary, they were delisted if, despite fulfilling KCH criteria, their clinical condition significantly improved or deteriorated.
Long Term immunosuppression was managed following the same strategy for all the patients, according with Royal Free Hospital internal protocol. In general, Tacrolimus was used as the first line drug. Prednisolone was used at a dose of 20mg per day and tapered and stopped within the first 3 months. In patients with autoimmune hepatitis or early rejection episodes, additional mycophenylate mofetil or azathioprine was administered. In patients with renal dysfunction post-transplantation, additional Basiliximab was used for the first week. In patients not able to tolerate Tacrolimus, Cyclosporine was used. Episodes of cellular rejection were treated with 3 boluses of IV methylprednisolone (1g/day for 3 consecutive days).
Patient Selection, clinical characteristics and data collection
All adult (over 18 years of age) patients with ALF admitted to ICU or the liver unit at the Royal Free Hospital between January 1990 and September 2014 were included. Individual case notes were reviewed by 2 investigators independently and data collected for patient demographics, aetiology of ALF, relevant laboratory and clinical parameters including organ
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This article is protected by copyright. All rights reserved. system support, severity of illness assessment (including KCH criteria) on the day of admission and then daily (until spontaneous recovery, death or ELT), management (spontaneous survival or ELT) and short-term (90 days) and long-term outcome. In order to assess the long-term mortality without any bias related to the acute condition, only patients that were alive after 90 days from the ICU admission were considered for this study (early survivors, ES). Patients were followed up for long-term outcomes until May 2015, the end of study period. ES were grouped into 4 cohorts: APAP ELT (acetaminophen overdose patients treated with liver transplantation), APAP SS (acetaminophen overdose patients managed conservatively or spontaneous survivors), nAPAP ELT (non-acetaminophen overdose patients treated with liver transplantation) and nAPAP SS (non-acetaminophen overdose ALF patients managed conservatively or spontaneous survivors).
Statistical analysis
Statistical analysis was performed using SPSS version 22.0 (Spss Inc., Chicago, IL). Mean and standard deviation for parametric and median and range for non-parametric descriptive variables, Chi Square or Fisher test (categorical variables) and ANOVA or Kruskal Wallis test (continuous variables) to compare baseline characteristics between 4 cohorts and to compare differences in their outcomes, were applied. To estimate the cumulative survivals, Kaplan Meier analysis (Log Rank test) was used. Threshold value p < 0.05 was considered for 95% confidence interval.
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This article is protected by copyright. All rights reserved. In total, 87/200 patients died (43.5%). The majority of deaths, 76/87 (87.4%), occurred within the first 90 days of ICU admission (called Early Deaths, ED) and 70.1% within 21 days of ICU admission ( Supplementary Figure 1) . The median survival time was 6.5 days (range 0-57 days, IQR 15 days). The causes of death in the patients who died within 90 days (ED) were related to the severity of the acute condition (Supplementary Table 1 ). For the ED, the cause of death was related to persistent MOF in 67% of cases (one third with evidence of sepsis) and to brain oedema in 10.5%. Thirty one percent of the transplanted patients (21/70) died within 90 days but only 10/21 within 21 days of ICU admission. The main cause of death in the ED who had been transplanted was persistence of MOF despite surgery (14/21, 66.7%), 57% with evidence of sepsis. 
RESULTS

Patients
Early Survivors
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This article is protected by copyright. All rights reserved. Baseline characteristics of ES patients detected at the time of ICU admission are described in Table 1 . In 61/124, 49.2% ES, APAP was the cause of ALF. nAPAP SS cohort was younger.
Organ failures and need for organ support were similar between the groups, except for renal replacement therapy (RRT). The need for mechanical ventilation at the time of ICU admission was more frequent for the APAP ELT cohort (92.3%), but no differences were noted according to the ventilatory settings and gas exchange parameters, compared to the other cohorts. Serum creatinine values were higher and need for RRT more frequent in APAP patients. All the transplanted patients, independently of ALF aetiology, had more deranged coagulation parameters and higher serum bilirubin. Metabolic impairment and acid-base disturbance was more severe in APAP ELT patients and WCC was significantly higher in nAPAP SS patients. Patients treated with ELT, at the time of ICU admission, had a higher
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MELD score and more frequently fulfilled the KCH criteria. APACHE2 and SOFA scores at the time of ICU admission were higher in APAP ELT patients.
Long-term outcome of the ES patients 11/124 ES patients died during the follow up (8.9%), 8/11 (72.7%) were treated with ELT (p=0.025) ( Figure 2 ). For the patients who died, the median survival was 5.3 years (range 92 days -12.4 years, IQR 9.1 years). The first non-ELT death was registered after 8.2 years of follow up. Figure 3 represents the estimated overall survival, using the Log Rank test, which shows a significantly higher expected mortality in ELT patients. Figure 3a , compares the total ELT with the SS patients in those that survived 90-days (ES), confirming a better outcome for SS patients (p=0.029). Considering the ES stratified according to ALF aetiology and management (Figure 3b ), KM survival curves confirms a worse outcome for APAP patients managed with ELT, and a better outcome for APAP patients treated conservatively (p=0.003). These findings were confirmed when patients were analysed separately according to ALF aetiology (p=0.005 and 0.160 respectively for APAP and nAPAP aetiology, Figure 3c and 3d). The worse survival of patients undergoing ELT was confirmed even when considering only the APAP patients fulfilling the KCH criteria ( Figure 4 , p=0.014). In nAPAP patients the trend confirmed a worse outcome for transplanted patients although the difference was not statistically significant ( Figure 3d ). However, subgroup analysis considering the ALF type (hyperacute/acute/subacute) showed that only the patients with subacute ALF (12/124, 9.7%) had benefits from ELT (11/12, 91.7%,) in 90-day and overall survival (p=0.024 respectively, no patient dying after the 90th day from ICU admission, data not shown) compared to those managed conservatively.
This article is protected by copyright. All rights reserved. Table 2 shows the main features of ES patients who died. All the ALF events were homogeneously distributed between 1994 and 2010. 3/11 patients were older than 45 and 7/11 were female. 8/11 patients (72.7%) who died had an APAP related ALF ( Figure 2 ); 3/11 had an indeterminate cause of ALF. The cause of death was related to graft failure or immunosuppression in 6/8 LT patients (Table 3a) Among the 3 non-transplanted patients who died, 2/3 had a severe psychiatric history (Table   4 ). 1/3 did not meet KCH and died from suicide. 2/3 had not been transplanted in spite of meeting KCH because of clinical improvement and ineligibility respectively. One of these patients died from an unknown cause and the second from suicide (APAP intoxication).
Causes of death in ES patients
DISCUSSION
ALF can rapidly evolve into multi organ failure and lead to death through multiple mechanisms. [1] [2] [3] ELT is often a lifesaving option for some patients, 4 but it is a high-risk procedure, both in the immediate perioperative period and in the longer-term, mainly due to complications of immunosuppression. [16] [17] [18] [19] The short-term outcomes have improved over the years
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This article is protected by copyright. All rights reserved. from less than 20% hospital survival in the pre-transplantation era to up to more than 70% currently. 8, 10, 20 Similar improvements with time have also been registered for those treated conservatively. 8, 10, 20, 21 Consequently, it is important to be able to identify the sub-cohort of the patient who might recover without ELT amongst those deemed at high risk of death without ELT. 6, 21 KCH Criteria has been the most widely validated score and the most widely used criteria in clinical practice and in the UK is used to define the group of patients with ALF that may benefit from ELT. 6, 22, 23 Several studies have shown a better long-term outcome for ALF patients treated with ELT once they survive the acute post-operative period compared to patients transplanted for chronic liver failure, 17, 19, 24 but data about the long-term mortality of SS are limited. Consequently, considerations about the long-term outcome are currently not taken into account in the decision-making process for ALF management. In contrast to the recently published study, 15 the present study suggests that the long-term outcome for ALF patients who survive at the first 90 days from the ICU admission is better for the SS compared to the patients treated with ELT.
In order to evaluate the long-term outcomes, Fontana et al. 15 enrolled ALF patients who survived 3 weeks from the onset of the syndrome. Their study suggested that the mortality of SS over the long-term was higher than those that underwent ELT. The first main differences of the paper of Fontana et al. stems from the multicenter nature of the study that did not allow determination of the cause of mortality for more than 50% of the patients and the second from the choice of the timing of starting the analysis, i.e. from 3-weeks of the onset of ALF.
As previously described 5, 12, 17, 19, 25 and confirmed by this study ( Supplementary Figure 1 and Supplementary Table 1 ), ALF mortality is very high during the first 90 days from ICU ad-
This article is protected by copyright. All rights reserved. mission and related to events derived from the condition of the acute phase response developed during the SIRS, often persistent in spite of ELT. Thus, the mortality that occurs in this early period following diagnosis of ALF, both for SS and ELT ALF patients, is a potential confounder to assess long-term outcomes, and should be considered as mortality related to the illness itself or the effect of surgery. For this reason, we decided to define ES at 3-months and determine long-term outcome from this point forward.
This study suggests a greater likelihood of mortality over the long-term in the patients that underwent ELT compared with the SS patients ( Figure 3a ). Considering ALF aetiology and management together, the long-term survival confirms a higher mortality rate in APAP patients treated with ELT, even when considering only the patients fulfilling poor prognostic criteria (Figure 3b, Figure 3c and Figure 4 ). In contrast, the outcome of nAPAP treated with ELT was not significantly different to the SS patients, probably due to the low prevalence of deaths in this category (Figure 3d ). However, subgroup analysis showed that ELT improves the survival rate in patients presenting a subacute liver failure.
The main cause of death in the 3 patients in the SS group of ES patients was suicide in 2 and unknown cause in one, with no significant morbidity in the post recovery period. This was not surprising as all these patients had serious underlying psychiatric diseases and suicide resulted in 2 despite close follow up. In contrast, the ELT group of ES patients frequently died from graft related causes of death (graft failure or immunosuppression complication; 6/8, 75%). Additionally, the ELT patients had a longer ICU stay and 7/8 developed in-hospital and/or long-term post-LT co-morbidities, including requirement for re-transplantation, renal dialysis and need for kidney transplantation. Graft failure was registered in four patients and related to poor compliance with immunosuppressive therapy in two patients. All these data
suggest that APAP patients require on-going psychological support in the community. Factors predictive of poor long-term outcomes include use of marginal donors and the use of extended criteria donor graft features. 11, 27, 30 As shown in Table 3b , only good quality grafts were used with only 2 patients being over 65 years in the patients that died. In the SS group, the first death was registered after 8-years from the ALF episode suggesting complete regeneration and recovery of liver function in this group of patients. 24, 28, 29 These findings are particularly relevant given the high risks of performing unnecessary LT. As shown in Figure 2 , 38/92 patients fulfilling KCH criteria (41%), mainly APAP related, were not transplanted because of clinical improvement, suggesting lack of specificity of the criteria.
Although the low number of long term deaths does not allow definitive conclusions and indepth statistical analysis to search for predictors of long-term mortality, the availability of sequential data in all ALF patients admitted to a single ICU provides robust evidence to question the previous observation of high rate of long-term mortality in SS. The analysis of the causes of death shows that a cut-off of 21 days is inappropriate in defining the long-term mortality, as this is likely to reflect the acute phase of the illness. In conclusion, the results of this study suggest that beyond the first 90-days following the occurrence of ALF, patients treated with SS have a better long-term outcome compared with those treated with ELT. This data underlines the importance of identifying new tools to select patients for ELT as well as the urgent need for novel therapies to increase the proportion of spontaneous survivors.
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